Nicole Germino
Stock Analyst at Truist Securities
(2.59)
# 1,349
Out of 4,667 analysts
18
Total ratings
33.33%
Success rate
1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterates: Buy | $100 → $105 | $72.67 | +44.49% | 7 | Nov 1, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $21 | $4.40 | +377.27% | 1 | Sep 25, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $21 | $10.54 | +99.24% | 1 | Jun 28, 2024 | |
| SGMO Sangamo Therapeutics | Downgrades: Hold | n/a | $1.95 | - | 4 | Nov 7, 2023 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $15.02 | +59.79% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $13.55 | - | 2 | Sep 3, 2021 |
Insmed
Nov 1, 2024
Reiterates: Buy
Price Target: $100 → $105
Current: $72.67
Upside: +44.49%
Perspective Therapeutics
Sep 25, 2024
Initiates: Buy
Price Target: $21
Current: $4.40
Upside: +377.27%
Y-mAbs Therapeutics
Jun 28, 2024
Initiates: Buy
Price Target: $21
Current: $10.54
Upside: +99.24%
Sangamo Therapeutics
Nov 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.95
Upside: -
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $15.02
Upside: +59.79%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $13.55
Upside: -